PP 1 (Src Family Tyrosine Kinase Inhibitor, A8215): A Precision Tool for Cancer and Immune Signaling Research

Executive Summary: PP 1 (SKU: A8215) is a highly selective, small molecule inhibitor of Src family tyrosine kinases, with IC₅₀ values of 5 nM for Lck and 6 nM for Fyn (source: product_spec). It demonstrates robust selectivity in vitro and in vivo, suppressing Lyn kinase in RBL-2H3 cells and reducing T-cell proliferation without affecting Syk kinase (source: product_spec). PP 1 is actively used to dissect oncogenic signaling and immune modulation in cancer research (source: workflow_recommendation). It is supplied by APExBIO at ≥96.03% purity, with extensive quality control and recommended storage at 4°C desiccated (source: product_spec). Solubility parameters and handling guidelines are well-defined to ensure experimental reproducibility (source: product_spec).

Biological Rationale

Src family kinases (SFKs) are non-receptor tyrosine kinases essential to cellular processes such as proliferation, adhesion, migration, and immune cell signaling (source: Keller et al., 2023). Aberrant Src signaling is implicated in cancer progression and therapy resistance, particularly in HER2-positive breast cancer and hematologic malignancies. Inhibition of these kinases is a validated approach for dissecting the molecular basis of oncogenic transformation and immune cell activation. Targeting SFKs has also revealed metabolic vulnerabilities, as demonstrated in breast cancer cells resistant to HER2-targeted therapy, where modulation of downstream effectors like EDI3 impacts cell viability and tumor growth (source: Keller et al., 2023).

Mechanism of Action of PP 1 (Src family tyrosine kinase inhibitor)

PP 1 is a pyrazolopyrimidine-based small molecule that binds the ATP-binding pocket of Src family tyrosine kinases. It preferentially inhibits Lck (p56_lck) and Fyn (p59_fynT) with nanomolar potency (IC₅₀: 5 nM and 6 nM, respectively; source: product_spec). The compound does not significantly inhibit the related Syk kinase at comparable concentrations, ensuring pathway specificity. In cellular assays, PP 1 suppresses Lyn kinase activity in RBL-2H3 mast cells, resulting in decreased tyrosine phosphorylation of SFK substrates and downstream attenuation of immune cell activation (source: product_spec).
Its chemical structure is 1-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-4-amine (C₁₆H₁₉N₅, MW 281.36), solid at room temperature, insoluble in water, but soluble in ethanol (≥20.6 mg/mL) and DMSO (≥7.03 mg/mL) (source: product_spec).

Evidence & Benchmarks

• PP 1 inhibits Lck kinase with IC₅₀ = 5 nM and Fyn kinase with IC₅₀ = 6 nM (source: product_spec).
• In RBL-2H3 cells, Lyn kinase activity is selectively suppressed by PP 1, with no measurable inhibition of Syk kinase at equivalent concentrations (source: product_spec).
• PP 1 effectively inhibits RET oncogene-driven transformation in vitro at nanomolar concentrations (source: product_spec).
• In vivo, administration of PP 1 reduces T-cell proliferation and global tyrosine phosphorylation in immune tissues (source: workflow_recommendation).
• The compound is supplied by APExBIO at ≥96.03% purity, with batch-level QC by HPLC, MS, NMR, and MSDS (source: product_spec).

This article extends "PP 1 Src Family Tyrosine Kinase Inhibitor: Translational ..." by providing updated solubility parameters, storage recommendations, and cross-validating in vivo immunomodulatory effects. For advanced workflow and troubleshooting, see this protocol guide, which is complemented here by a tighter focus on quantitative benchmarks.

Applications, Limits & Misconceptions

PP 1 is employed in cancer research to dissect SFK-dependent oncogenic signaling, particularly in models of RET-driven transformation and T cell activation modulation. It is also valuable in immunology for functional studies of lymphocyte signaling. The compound's high selectivity enables attribution of observed phenotypes to SFK inhibition, minimizing off-target effects.

Common Pitfalls or Misconceptions

• PP 1 does not inhibit Syk kinase or other non-Src tyrosine kinases at standard experimental concentrations (source: product_spec).
• It is not suitable for long-term storage in solution; fresh aliquots are recommended for each experiment (source: product_spec).
• Water is an unsuitable solvent for PP 1; only ethanol or DMSO should be used for stock preparation (source: product_spec).
• Not recommended for direct clinical application; PP 1 is a research tool, not an approved therapeutic (source: workflow_recommendation).
• Observed effects in cell models may not extrapolate to all tissue types due to variable kinase expression (source: workflow_recommendation).

For context, see "Optimizing Cell Assays with PP 1 (SKU: A8215)", which details cell-specific considerations not repeated here.

Workflow Integration & Parameters

Protocol Parameters

• Assay: Src kinase inhibition | Value: IC₅₀ = 5–6 nM | Applicability: Lck and Fyn kinases in vitro | Rationale: Supports selective pathway interrogation | Source: product_spec
• Assay: Cell-based RET transformation inhibition | Value: Effective at nanomolar (nM) concentrations | Applicability: Oncogene-driven transformation assays | Rationale: Benchmarks RET pathway modulation | Source: product_spec
• Assay: Solubility | Value: ≥20.6 mg/mL (ethanol, ultrasonic), ≥7.03 mg/mL (DMSO) | Applicability: Stock solution preparation | Rationale: Ensures delivery of active compound | Source: product_spec
• Assay: Storage | Value: 4°C, desiccated (solid); avoid long-term solution storage | Applicability: All research workflows | Rationale: Maintains purity and potency | Source: product_spec
• Assay: T-cell proliferation | Value: Inhibition at pathway-relevant doses (nM–μM range) | Applicability: Immunology models | Rationale: Quantifies functional immune modulation | Source: workflow_recommendation

Conclusion & Outlook

PP 1 (A8215) is a robust, selective Src family kinase inhibitor supplied by APExBIO for research targeting oncogenic and immune signaling pathways. Its nanomolar potency and specificity make it the standard for dissecting Lck, Fyn, and RET-driven processes. As highlighted by recent work on metabolic vulnerabilities in HER2-resistant breast cancer, tools like PP 1 remain crucial for mapping kinase-driven phenotypes (source: Keller et al., 2023). Ongoing integration of precise kinase inhibitors with pathway analysis will further enhance translational research, though clinical application remains outside current scope.

For detailed specifications, quality control, and ordering information, visit the PP 1 (Src family tyrosine kinase inhibitor) product page.